KINGSEY FALLS, QC, Nov. 7, 2024 - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended September 30, 2024.
Q3 2024 Highlights
- Sales of $1,201 million (compared with $1,180 million in Q2 2024 and $1,198 million in Q3 2023);
- Operating income of $36 million (compared with $34 million in Q2 2024 and $80 million in Q3 2023);
- Net earnings per common share of $0.01 (compared with $0.01 in Q2 2024 and $0.34 in Q3 2023);
- Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A)1) of $140 million (compared with $112 million in Q2 2024 and $161 million in Q3 2023);
- Adjusted net earnings per common share1 of $0.27 (compared with $0.08 in Q2 2024 and $0.44 in Q3 2023);
- Net debt1 of $2,039 million as of September 30, 2024 (compared with $2,093 million as of June 30, 2024). Net debt to EBITDA (A) ratio1 of 4.3x, versus from 4.2x as of June 30, 2024;
- Total capital expenditures, net of disposals, totaled $34 million in Q3 2024, compared to $23 million in Q2 2024 and $56 million in Q3 2023. The Corporation's 2024 capital expenditures will be approximately $160 million.
Hugues Simon, President and CEO, commented: "We are pleased with our third quarter 2024 performance. Sequentially stronger results were driven by our Containerboard business, where higher average selling prices and lower production expenses offset the impact of higher raw material costs. Specialty Products results were stable, with stronger selling prices fully mitigating raw material cost and sales mix headwinds. As forecasted, third quarter Tissue Papers results were lower than the previous quarter due to higher average raw material costs and lower pricing related to the expected changes in the mix of products sold."
Discussing near-term outlook, Mr. Simon commented, "We expect fourth quarter results in each of our packaging business segments to be stable sequentially, as benefits from lower raw material costs and previously announced selling price increases will be offset by lower seasonal volumes. In Tissue Papers, slightly stronger sequential results are expected to benefit from lower average raw material costs, slightly stronger volumes, and selling price increase tailwinds offset by the impact from seasonal changes in sales mix.
As we look toward the medium and longer-term, we are focused on growing sustainable value for shareholders. Central to this is driving and capturing efficiency across our operational platforms, most notably by the ongoing scale-up of production at our Bear Island facility and ramp-up of our recently installed tissue converting lines. Prioritizing these areas, in conjunction with leveraging additional production capacity in all of our facilities through numerous efficiency optimization initiatives, will drive cash flow generation and debt reduction, both of which are key action areas across the Company. We will be all the more better positioned to deliver on both fronts as we implement the changes announced on October 30, and look forward to sharing details of our areas of strategic focus for the next 18 to 24 months in early 2025."
Source: Cascades